ASFA’s Tenth Special Issue refreshes the evidence base for therapeutic apheresis
The American Society for Apheresis has again tightened the frame around one of medicine’s most specialized treatment modalities: therapeutic apheresis. The Tenth Special Issue of the Journal of Clinical Apheresis keeps the familiar fact-sheet format while updating how clinicians should think about evidence, grading, and indication categories across a wide range of diseases and conditions.
The new edition is not a cosmetic revision. It preserves the evidence-based approach that has shaped recent ASFA editions and extends it across 93 fact sheets and 183 graded and categorized indications. Two new fact sheets have been added, and several existing indications have been reclassified or had their grade changed. In a field where treatment decisions often hinge on a narrow evidence base, those shifts can alter bedside practice, referral patterns, and institutional protocols.
Apheresis remains a procedure-driven therapy rather than a disease-agnostic intervention. It is selected when removing or exchanging blood components, plasma constituents, or pathogenic circulating factors is biologically plausible and clinically justified. The ASFA framework is built to separate situations where the procedure is strongly supported from those where it is used selectively, where the evidence is weak, or where benefit is uncertain. For clinicians, that distinction matters because apheresis is resource-intensive, operator-dependent, and not interchangeable with drug therapy.
A fact-sheet model built for real-world decisions
The committee kept the general layout introduced in the Fourth Edition in 2007. Each fact sheet condenses the evidence for a specific disease entity or medical condition into a practical summary that can be used by hematologists, neurologists, nephrologists, transfusion specialists, and other clinicians who encounter complex referral questions. In a specialty that spans autoimmune disease, hematologic emergencies, transplant complications, and neurologic syndromes, the value of a standardized evidence summary is obvious: it limits interpretive drift and makes the rationale for apheresis easier to compare across indications.
The committee’s process also signals how the field is maturing. Earlier editions established the principle that therapeutic apheresis should not be treated as a catch-all rescue maneuver. This edition continues that discipline by using systematic review methods and evidence grading to support categorization. Such a structure is especially important when randomized evidence is sparse, because apheresis is often studied in small cohorts, rare diseases, or settings where trials are difficult to run.
One sentence captures the clinical stakes: apheresis is still indispensable in some conditions, but it should not be assumed to help simply because it can be performed.
93 fact sheets, 183 indications, and a handful of meaningful changes
The most concrete output of the Tenth Special Issue is its scope. With 93 fact sheets and 183 graded indications, the document functions as a broad reference for clinicians who need to know whether apheresis is appropriate, whether the evidence supports routine use, or whether the therapy should be reserved for selected cases. The addition of two new fact sheets suggests that the evidence base has expanded enough to justify formal inclusion of new disease categories or therapeutic scenarios.
The changes to existing indications, categorization, or grade are just as important as the additions. Even without a list of every revised disease category in the abstract, those adjustments imply a living document shaped by new studies, reinterpretation of older data, and periodic reassessment of clinical utility. In practice, an upgraded grade can influence whether a hospital supports the procedure, how apheresis services are staffed, and whether clinicians pursue the intervention early or only after other options fail.
Apheresis recommendations are especially sensitive to biology. When the target is a circulating pathogenic antibody, immune complex, lipoprotein, or other removable factor, the logic of treatment is straightforward: reduce the burden of the causative substrate and alter the disease trajectory. When the mechanism is less direct, the burden of proof rises. The ASFA grading system exists to keep those situations distinct rather than collapsing them into a single label of “possible benefit.”
Why the update matters for specialty practice
The practical value of this special issue extends well beyond transfusion medicine. Neurologists may use it when considering plasma exchange in immune-mediated disorders. Nephrologists may consult it for thrombotic microangiopathy or other renal syndromes where extracorporeal removal has a mechanistic role. Hematologists face it in disorders of plasma constituents, hemolysis, or immune dysregulation. Transplant teams may need it when a circulating factor threatens graft survival.
The guidance also helps institutions avoid two common errors. The first is overuse, where apheresis is deployed for conditions with weak or no supporting evidence simply because the patient is severely ill. The second is underuse, where a potentially helpful procedure is delayed because local practice has not kept pace with updated categorization. Both errors carry consequences. Overuse consumes scarce resources and exposes patients to procedural risk. Underuse can leave a treatable pathophysiologic driver untouched while disease progresses.
For that reason, the issue reads less like a passive catalogue and more like an operational tool for multidisciplinary care. It offers a common language for evidence grade, indication category, and disease-specific nuance. In a domain where practice varies by center, that shared language helps align consultation decisions with the current literature rather than with habit alone.
A reference document built to guide restraint as much as use
The committee’s stated aim is to continue serving as a key resource for the utilization of therapeutic apheresis in human disease. That goal is modest in wording and substantial in consequence. Apheresis is often most valuable when it is used precisely, at the right time, for the right indication, and with a clear understanding of what the procedure can and cannot accomplish. The Tenth Special Issue keeps that principle intact while broadening the evidence map clinicians rely on.
The main limitation is embedded in the nature of the field itself: many indications for apheresis remain anchored in low-volume studies, observational data, and disease-specific expert synthesis rather than large randomized trials. The special issue responds to that reality by grading evidence instead of pretending every indication rests on the same foundation. The next practical question for clinicians is how individual institutions will translate the updated categories into local policy, training, and access pathways.
The review itself gives no simple endpoint for closure. It instead leaves a working standard: use apheresis where the evidence and biology support it, and reserve it where they do not.
- • Journal of Clinical Apheresis DOI 10.1002/jca.70141: https://doi.org/10.1002/jca.70141